JP4776474B2 - Herbal medicine composition - Google Patents
Herbal medicine composition Download PDFInfo
- Publication number
- JP4776474B2 JP4776474B2 JP2006233544A JP2006233544A JP4776474B2 JP 4776474 B2 JP4776474 B2 JP 4776474B2 JP 2006233544 A JP2006233544 A JP 2006233544A JP 2006233544 A JP2006233544 A JP 2006233544A JP 4776474 B2 JP4776474 B2 JP 4776474B2
- Authority
- JP
- Japan
- Prior art keywords
- herbal medicine
- herbal
- nicotine
- present
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
本発明は、喫煙関連物質及びダイオキシンに対する解毒作用、並びに抗酸化作用を有する生薬組成物に関するものである。 The present invention relates to a herbal composition having a detoxifying action and an antioxidant action against smoking-related substances and dioxins.
種々の薬理作用を発揮させることを目的として、生薬の抽出物を複数組み合わせた生薬組成物が種々提案されており、例えば、黒豆、蒲公英及び金銀花の抽出物からなる生薬組成物は、体内ニコチン及びダイオキシンに対する分解効果を有することが記載されている（特許文献１参照）。 For the purpose of exerting various pharmacological actions, various herbal compositions in which a plurality of herbal extracts are combined have been proposed. For example, herbal compositions composed of extracts of black beans, koei kan and gold and silver flowers are nicotine in the body. And having a decomposition effect on dioxins (see Patent Document 1).
しかしながら、喫煙関連物質としては、ニコチン以外にタールや一酸化炭素などがあり、ニコチンに対する解毒作用を有するだけでは、効果として十分とはいえない。また、近年は、老化、生活習慣病や発ガンなどを予防するため、抗酸化剤が注目されており、上記の作用に加えて抗酸化作用を併せて有する生薬組成物が要望されている。 However, smoking-related substances include tar and carbon monoxide in addition to nicotine, and merely having a detoxifying action against nicotine is not sufficient as an effect. In recent years, antioxidants have attracted attention in order to prevent aging, lifestyle-related diseases, carcinogenesis, and the like, and there is a demand for a herbal composition having an antioxidant action in addition to the above actions.
本発明は、上記事情に鑑みてなされたものであり、その目的は、ニコチン、タール、一酸化炭素などの喫煙関連物質及びダイオキシンに対する解毒作用、並びに抗酸化作用を有する生薬組成物を提供することにある。 The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a herbal medicine composition having a detoxifying action and an antioxidant action against smoking-related substances such as nicotine, tar and carbon monoxide and dioxin. It is in.
本発明者は、タンポポ、トウキンセン、イヌホオズキ、茶の木、オオバコ、どくだみ、スイカズラ及びカンゾウの抽出物を含有する生薬組成物に着目し、その効能を鋭意検討したところ、喫煙関連物質及びダイオキシンに対する解毒作用、並びに抗酸化作用を有することを見出し、本発明を完成した。 The present inventor paid attention to a herbal medicine composition containing extracts of dandelion, eucalyptus, physalis, tea tree, psyllium, dokudomi, honeysuckle and licorice. The present invention was completed by finding that it has an action and an antioxidant action.
すなわち、本発明の要旨は以下のとおりである。
〔１〕 タンポポ、トウキンセン、イヌホオズキ、茶の木、オオバコ、どくだみ、スイカズラ及びカンゾウの抽出物を含有することを特徴とする、ニコチン、タール、一酸化炭素及びダイオキシンに対する解毒、並びに抗酸化のための生薬組成物、
〔２〕 前記〔１〕記載の生薬組成物を含有し、ニコチン、タール、一酸化炭素及びダイオキシンに対する解毒、並びに抗酸化のための医薬品、
〔３〕 前記〔１〕記載の生薬組成物を含有し、ニコチン、タール、一酸化炭素及びダイオキシンに対する解毒、並びに抗酸化のための漢方薬。
That is, the gist of the present invention is as follows.
[1] For detoxification against nicotine, tar, carbon monoxide and dioxins, and for antioxidants, characterized by containing extracts of dandelion, eucalyptus, physalis, tea tree, plantain, donut, honeysuckle and licorice Herbal medicine composition,
[2] A medicinal composition containing the herbal composition according to the above [1] , for detoxification against nicotine, tar, carbon monoxide and dioxin, and antioxidant ,
[3] A herbal medicine containing the herbal composition according to the above [1] for detoxification and antioxidant against nicotine, tar, carbon monoxide and dioxin .
本発明によれば、ニコチン、タール、一酸化炭素などの喫煙関連物質及びダイオキシンに対する解毒作用、ならびに抗酸化作用を有する生薬組成物を提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, the herbal medicine composition which has the detoxification effect | action with respect to smoking related substances, such as nicotine, tar, carbon monoxide, and dioxin, and an antioxidant effect | action can be provided.
本発明の生薬組成物は、タンポポ、トウキンセン、イヌホオズキ、茶の木、オオバコ、どくだみ、スイカズラ及びカンゾウの抽出物を必須成分として含有し、ニコチン、タール、一酸化炭素などの喫煙関連物質及びダイオキシンに対する解毒作用、並びに抗酸化作用を有するものである。 The herbal medicine composition of the present invention contains extracts of dandelions, quince, physalis, tea trees, psyllium, donuts, honeysuckle, and licorice as essential components, and is used for smoking-related substances such as nicotine, tar, carbon monoxide, and dioxins. It has a detoxification action and an antioxidant action.
タンポポ(Taraxacum platycarpum H. dahist)は、蒲公英とも称されるキク科の多年草である。本発明の生薬組成物において、タンポポの抽出物は、全必須成分中、０．５〜２０重量％含有させることが好ましい。本発明において、タンポポの使用部位は特に限定されないが、通常は、根、花、全草、葉が使用される。 Dandelion (Taraxacum platycarpum H. dahist) is a perennial plant belonging to the family Asteraceae, also known as Koei. In the herbal medicine composition of the present invention, the dandelion extract is preferably contained in an amount of 0.5 to 20% by weight in all essential components. In the present invention, the use site of the dandelion is not particularly limited, but usually roots, flowers, whole grasses, and leaves are used.
トウキンセン（Calendula officinalis L.）は、金松花とも称されるキク科の一年草である。本発明の生薬組成物において、トウキンセンの抽出物は、全必須成分中、５〜４０重量％含有させることが好ましい。本発明において、トウキンセンの使用部位は特に限定されないが、通常は、花が使用される。 Cowkinsen (Calendula officinalis L.) is an annual plant of the asteraceae family also referred to as a gold pine flower. In the crude drug composition of the present invention, it is preferable to contain 5 to 40% by weight of the extract of tokinsen in all essential components. In the present invention, the use site of eucalyptus is not particularly limited, but normally flowers are used.
イヌホオズキ（Solanum nigrum L.）はナス科の１年草である。本発明の生薬組成物において、イヌホオズキの抽出物は、全必須成分中、５〜２０重量％含有させることが好ましい。本発明において、イヌホオズキの使用部位は特に限定されないが、通常は、全草が使用される。 The dogwood (Solanum nigrum L.) is an annual plant of the solanaceous family. In the herbal medicine composition of the present invention, it is preferable to contain 5 to 20% by weight of the dogwood adzuki bean extract among all the essential components. In the present invention, the use site of the dogwood is not particularly limited, but the whole plant is usually used.
茶の木（Thea sinensis L）はツバキ科の常緑樹である。本発明の生薬組成物において、茶の木の抽出物は、全必須成分中、５〜２０重量％含有させることが好ましい。本発明において、茶の木の使用部位は特に限定されないが、通常は、葉が使用される。 Tea tree (Thea sinensis L) is an evergreen tree of the camellia family. In the herbal composition of the present invention, the tea tree extract is preferably contained in an amount of 5 to 20% by weight in all essential components. In the present invention, the use site of the tea tree is not particularly limited, but usually leaves are used.
オオバコ（Plantago asiatica L.）はオオバコ科の多年草である。本発明の生薬組成物において、オオバコの抽出物は、全必須成分中、５〜４０重量％含有させることが好ましい。本発明において、オオバコの使用部位は特に限定されないが、通常は、草が使用される。 Plantain (Plantago asiatica L.) is a perennial plant in the plantain family. In the herbal medicine composition of the present invention, it is preferable that the extract of psyllium is contained in an amount of 5 to 40% by weight in all essential components. In the present invention, the use site of psyllium is not particularly limited, but normally grass is used.
どくだみ（Houttuynia cordata Thunb (Polypara cordata Bueck)）は、中薬草とも称されるドクダミ科の多年草である。本発明の生薬組成物において、どくだみの抽出物は、全必須成分中、５〜４０重量％含有させることが好ましい。本発明において、どくだみの使用部位は特に限定されないが、通常は、幹と葉が使用される。 Dodomi (Houttuynia cordata Thunb (Polypara cordata Bueck)) is a perennial plant belonging to the family Dokudami, also called a medicinal herb. In the herbal medicine composition of the present invention, it is preferable that the dodomi extract is contained in an amount of 5 to 40% by weight in all essential components. In the present invention, the use site of the dodge is not particularly limited, but usually a trunk and a leaf are used.
スイカズラ(Lonicera japonica Thunb)は、金銀花とも称されるスイカズラ科のつる性植物である。本発明の生薬組成物において、スイカズラの抽出物は、全必須成分中、５〜３０重量％含有させることが好ましい。本発明において、スイカズラの使用部位は特に限定されないが、通常は、幹と葉が使用される。 Honeysuckle (Lonicera japonica Thunb) is a vine plant of the family Honeysuckle, also called gold and silver flowers. In the herbal medicine composition of the present invention, the extract of honeysuckle is preferably contained in an amount of 5 to 30% by weight in all essential components. In the present invention, the use site of honeysuckle is not particularly limited, but usually a trunk and a leaf are used.
カンゾウ(Glycyrrhiza glabra L.)は、国老，敏感草とも称されるマメ科の多年草である。本発明の生薬組成物において、カンゾウの抽出物は、全必須成分中、０．５〜２０重量％含有させることが好ましい。本発明において、カンゾウの使用部位は特に限定されないが、通常は、根と根茎が使用される。 Daylily (Glycyrrhiza glabra L.) is a leguminous perennial that is also referred to as the old and sensitive grass. In the herbal medicine composition of the present invention, the extract of licorice is preferably contained in an amount of 0.5 to 20% by weight in all essential components. In the present invention, the use site of licorice is not particularly limited, but usually roots and rhizomes are used.
次に、本発明の生薬組成物の製法について説明する。上述した各生薬の抽出物は、常法によって製造することができる。例えば、上述した各生薬の乾燥物を細片にして、抽出溶媒中で還流抽出し、濾過、濃縮の各工程を経て各生薬の抽出物を得、各抽出物を所定含量で混合することにより生薬組成物（粉末）が得られる。また、還流抽出の際に、各生薬の乾燥物を所定量混合した混合物を用いて、上記と同様の工程により生薬組成物を製造することもできる。 Next, the manufacturing method of the crude drug composition of this invention is demonstrated. The above-described extracts of each herbal medicine can be produced by a conventional method. For example, the above-mentioned dried products of each herbal medicine are made into small pieces, refluxed and extracted in an extraction solvent, filtered and concentrated to obtain each herbal medicine extract, and each extract is mixed at a predetermined content. A crude drug composition (powder) is obtained. In addition, during the reflux extraction, a crude drug composition can be produced by the same process as described above, using a mixture obtained by mixing a predetermined amount of each crude drug dried product.
抽出溶媒としては、水、低級アルコール類（例えば、メタノール、エタノール、イソプロピルアルコール、ｎ−ブタノールなど）、エステル類（例えば、酢酸エチルなど）、ケトン類（例えば、アセトンなど）、芳香族炭化水素類、ハロゲン化脂肪族炭化水素類（例えば、クロロホルムなど）などが挙げられ、これらは単独で又は２種以上を混合して使用することができる。 Examples of the extraction solvent include water, lower alcohols (eg, methanol, ethanol, isopropyl alcohol, n-butanol), esters (eg, ethyl acetate), ketones (eg, acetone), aromatic hydrocarbons. , Halogenated aliphatic hydrocarbons (for example, chloroform) and the like, and these can be used alone or in admixture of two or more.
本発明の生薬組成物は、上述した粉末の混合物をそのまま、または適当な担体（例えば、乳糖、とうもろこし澱粉、微結晶セルロース、マグネシウムステアレイトなど）と混合して、例えば、粉末、細粒剤、錠剤、顆粒剤、カプセル剤、トローチ剤などの剤型にして供することができる。また、本発明の生薬組成物を食品中に含有させ、機能性食品として供することもできる。本発明の生薬組成物を含有させる食品としては、例えば、ヨーグルト、キャンデー、クッキー、ゼリー、チューインガムなどの菓子類、清涼飲料などが挙げられる。また、タバコ、医薬品、漢方薬に配合することもできる。本発明の生薬組成物を食品配合原料として用いる場合、その含有量は特に限定されないが、通常は、食品中５〜７０重量％の範囲で含有させることができる。 The herbal composition of the present invention can be prepared by mixing the above-mentioned powder mixture as it is or with an appropriate carrier (for example, lactose, corn starch, microcrystalline cellulose, magnesium stearate, etc.). It can be used in the form of tablets, granules, capsules, troches and the like. Moreover, the herbal medicine composition of this invention can be contained in foodstuffs and can also be provided as a functional foodstuff. Examples of the food containing the herbal composition of the present invention include confectionery such as yogurt, candy, cookies, jelly, chewing gum, and soft drinks. It can also be added to tobacco, pharmaceuticals, and herbal medicines. When the crude drug composition of the present invention is used as a food blending raw material, the content is not particularly limited, but it can usually be contained in the range of 5 to 70% by weight in the food.
以下、試験例などにより本発明をさらに詳しく説明するが、本発明はこれらによりなんら限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to test examples and the like, but the present invention is not limited thereto.
１．生薬組成物の製造例
タンポポ、トウキンセン、イヌホオズキ、茶の木、オオバコ、どくだみ、スイカズラ及びカンゾウの乾燥物をそれぞれ１００ｇずつ用意し、前記各生薬に水（抽出溶媒）を２Ｌずつ添加し、大気圧条件で２時間還流した。得られた各生薬の粗抽出液のうち、上部にある残物を濾過して各生薬抽出液を得、次いで該生薬抽出液を５０℃で減圧濃縮して各生薬抽出物（粉末）を得た。そして、８種類の生薬抽出物の粉末を全て同量ずつ混合して生薬組成物（本発明品）を製造した。
1. Preparation example of crude drug composition 100 g each of dried dandelion, eucalyptus, physalis, tea tree, plantain, dodomi, honeysuckle and licorice are prepared, and 2 L of water (extraction solvent) is added to each of the herbal medicines, and atmospheric pressure The mixture was refluxed for 2 hours. Of the obtained crude extract of each herbal medicine, the residue at the top is filtered to obtain each herbal extract, and then the herbal extract is concentrated under reduced pressure at 50 ° C. to obtain each herbal extract (powder). It was. Then, the same amount of the powders of the 8 kinds of herbal extracts were mixed together to produce a herbal composition (product of the present invention).
２．ニコチン毒性試験（１）
６週齢のＩＣＲマウス（セムタコ社、韓国京畿道烏山市）２０匹を５匹ずつ４つの群（Ｇ１〜Ｇ４）に分け、通常の固体飼料を水とともに２週間給餌して、試験に供した。
マウス飼育は、温度２４℃±１℃、湿度５５±５％、換気回数１２回／時間、明暗周期１２時間／日（朝８時点灯、夜８時消灯）に設定された鉄網飼育室で行なった。なお、後述する試験についてもマウス飼育は上記と同じ条件で行なった。
８週齢の前記ＩＣＲマウスのうち、Ｇ１とＧ２には通常の固体飼料に生薬組成物（本発明品）を１０重量％混ぜたもの（以下、「生薬配合飼料」という）を水とともに１週間給餌した。一方、Ｇ３とＧ４には、通常の固体飼料を水とともに１週間給餌した。
そして、９週齢の前記ＩＣＲマウスのうち、Ｇ１とＧ３にはニコチンを腹腔投与し（ニコチン濃度：３０ｍｇ／ｋｇ）、麻痺開始時間、発作開始時間、発作終了時間および死亡するまでの時間を測定した。そして、死亡または回復した試験動物から心臓採血して、血中ニコチン濃度を測定した。また、Ｇ２とＧ４には、ニコチンを腹腔投与し（ニコチン濃度：３０ｍｇ／ｋｇ）、その後前記生薬配合飼料を給餌した後、上記と同様に麻痺開始時間等を測定した。
血中ニコチン濃度は次のようにして測定した。まず、採血した血液にアンモニア水を添加してｐＨ９に調整し、カラム（EXTRELUT COLUMN，MERCK社）に１５分間維持させて、酢酸エチルで溶出し、得られた溶出液を減圧下で除去した。そして、得られた残渣に酢酸エチルを加えて分析試料とした。分析試料はガスクロマトグラフィーにより定量した。分析条件は次のとおりである。
（ガスクロマトグラフィー装置）5890 SERIES，FID装着、ＨＰ社（U.S.））
（カラム）２％ Tharmon1000＋１％ＫＯＨ ChromosorbWAM：8/100 meshを充填した長さ２ｍ、直径３ｍｍのガラスカラム
（カラム温度）１００℃
（キャリア気体）Ｎ２
（流速）６０ｍｌ／ｍｉｎ
表１に結果を示す。
2. Nicotine toxicity test (1)
Twenty 6-week-old ICR mice (Semutako, Ulsan-si, Gyeonggi-do, Korea) were divided into four groups (G1-G4) of 5 each, and a normal solid feed was fed with water for 2 weeks for testing. .
Mice are raised in a steel net breeding room set at a temperature of 24 ° C ± 1 ° C, humidity of 55 ± 5%, ventilation rate of 12 times / hour, and light / dark cycle of 12 hours / day (lights on at 8 am, lights off at 8 pm). I did it. In the test described below, the mice were raised under the same conditions as described above.
Among the 8 week old ICR mice, G1 and G2 were prepared by mixing 10% by weight of a herbal composition (the product of the present invention) with a normal solid feed (hereinafter referred to as “herbal medicine-containing feed”) for 1 week. I was fed. On the other hand, G3 and G4 were fed normal solid feed with water for one week.
Of the 9-week-old ICR mice, G1 and G3 were administered nicotine intraperitoneally (nicotine concentration: 30 mg / kg), and the time to start paralysis, seizure start time, seizure end time, and time to death were measured. did. Then, blood was collected from a test animal that died or recovered, and the blood nicotine concentration was measured. In addition, nicotine was intraperitoneally administered to G2 and G4 (nicotine concentration: 30 mg / kg), and then the herbal medicine-mixed feed was fed.
The blood nicotine concentration was measured as follows. First, aqueous ammonia was added to the collected blood to adjust the pH to 9, maintained in a column (EXTRELUT COLUMN, MERCK) for 15 minutes, eluted with ethyl acetate, and the resulting eluate was removed under reduced pressure. Then, ethyl acetate was added to the obtained residue to prepare an analytical sample. The analytical sample was quantified by gas chromatography. The analysis conditions are as follows.
(Gas chromatography equipment) 5890 SERIES, FID installed, HP (US))
(Column) 2% Tharmon 1000 + 1% KOH ChromosorbWAM: Glass column with a length of 2 m and a diameter of 3 mm packed with 8/100 mesh (column temperature) 100 ° C.
(Carrier gas) N 2
(Flow rate) 60ml / min
Table 1 shows the results.
ニコチン投与前に生薬組成物（本発明品）を給餌した生薬組成物群（Ｇ１，Ｇ２）と生薬組成物（本発明品）を給餌しなかった対照群（Ｇ３，Ｇ４）とを比べると、生薬組成物群では１０匹中９匹が発作終了後に回復したのに対し、対照群では１０匹とも発作終了後に死亡した。この結果から、生薬組成物の摂取がニコチンに対する解毒効果を高めることが分かった。
次に、ニコチン投与後に生薬組成物（本発明品）を投与した群（Ｇ２，Ｇ４）と投与しなかった群（Ｇ１，Ｇ３）とを比べると、前者では発作開始時間が遅延するとともに、死亡する場合であっても死亡時間が遅延した。
When comparing the herbal composition group (G1, G2) fed with the herbal composition (product of the present invention) and the control group (G3, G4) not fed with the herbal composition (present product) before nicotine administration, In the crude drug composition group, 9 out of 10 animals recovered after the end of the attack, whereas in the control group, 10 animals died after the end of the attack. From this result, it was found that the intake of the herbal medicine composition enhanced the detoxification effect on nicotine.
Next, comparing the group (G2, G4) to which the herbal medicine composition (product of the present invention) was administered after nicotine administration and the group (G1, G3) to which the herbal composition was not administered were compared, the seizure start time was delayed and death occurred in the former. Even if the death time was delayed.
３．ニコチン毒性試験（２）
血中ニコチン濃度の測定に代えて尿中ニコチン濃度を測定した以外は前記「２．ニコチン毒性試験（１）」と同様に行なった。表２に結果を示す。
3. Nicotine toxicity test (2)
The test was carried out in the same manner as in “2. Nicotine toxicity test (1)” except that the urine nicotine concentration was measured instead of the blood nicotine concentration. Table 2 shows the results.
生薬組成物群（Ｇ１，Ｇ２）と対照群（Ｇ３，Ｇ４）の尿中ニコチン濃度を対比すると、前者は後者に比べ、尿中ニコチン濃度が著しく高いことが分かった。この結果と、前記表１の血中ニコチン濃度の結果から、生薬組成物（本発明品）のニコチンに対する解毒作用は、ニコチンの排泄が促進されることによるものと推測された。 When the urine nicotine concentrations of the crude drug composition group (G1, G2) and the control group (G3, G4) were compared, it was found that the urine nicotine concentration was significantly higher in the former than in the latter. From this result and the results of blood nicotine concentration in Table 1, it was presumed that the detoxification action of the herbal medicine composition (product of the present invention) on nicotine was due to the promotion of nicotine excretion.
４．ニコチンの排泄量の測定
４週齢のＩＣＲマウス（セムタコ社、韓国京畿道烏山市）１２匹を生薬組成物群と対照群に各６匹ずつ分け、通常の固体飼料を水とともに１週間給餌した。
５週齢の生薬組成物群マウスには、１日目の１０時と１７時に前記生薬配合飼料を水とともに給餌するとともに、その日の１４時に、注射用滅菌蒸留水に１ｍｇ／ｍｌの濃度で溶解したニコチンを体重１ｋｇ当たり１０ｍｇ腹腔投与した。
そして、２日目の１０時に前記生薬配合飼料を水とともに給餌し、その日の１４時に尿を採取して尿中ニコチン濃度を測定した。尿中ニコチン濃度の測定は、前記「３．ニコチン毒性試験（２）」と同様に行なった。
一方、５週齢の対照群マウスには、通常の固体飼料を水とともに給餌した以外は前記生薬組成物群と同じ時刻に給餌およびニコチン投与して、尿中ニコチン濃度を測定した。表３に結果を示す。
4). Measurement of excretion of nicotine Twelve 4-week-old ICR mice (Semutako, Ulsan-si, Gyeonggi-do, Korea) were divided into a herbal medicine composition group and a control group, each of which was fed a normal solid feed with water for one week. .
The herbal medicine composition group mice at 5 weeks of age were fed the herbal medicine-containing feed with water at 10:00 and 17:00 on the first day, and dissolved in sterile distilled water for injection at a concentration of 1 mg / ml at 14:00 on that day. The nicotine was administered intraperitoneally at 10 mg / kg body weight.
Then, at 10:00 on the second day, the herbal medicine-mixed feed was fed with water, and urine was collected at 14:00 on that day to measure the urine nicotine concentration. The urine nicotine concentration was measured in the same manner as in “3. Nicotine toxicity test (2)”.
On the other hand, 5 week-old control group mice were fed and administered nicotine at the same time as the herbal composition group except that a normal solid feed was fed with water, and the urine nicotine concentration was measured. Table 3 shows the results.
生薬組成物群と対照群のニコチン濃度は、それぞれ前記表２のＧ２とＧ４と同様の値となり、生薬組成物（本発明品）の体外排泄作用を再確認することができた。 The nicotine concentrations in the crude drug composition group and the control group were the same values as G2 and G4 in Table 2, respectively, and the in vitro excretion effect of the crude drug composition (product of the present invention) could be reconfirmed.
５．タール毒性試験（１）
６週齢のＩＣＲマウス（セムタコ社、韓国京畿道烏山市）１０匹を５匹ずつ生薬組成物群（Ｇ１）と対照群（Ｇ２）に分け、通常の固体飼料を水とともに２週間給餌した。
８週齢の前記ＩＣＲマウスのうち、Ｇ１には１日目に前記生薬配合飼料を水とともに給餌した後、タールを体重１ｋｇ当たり１０ｍｇ腹腔投与し、以後７日間前記生薬配合飼料を給餌して、該期間中のマウスの様子を観察した。
一方、Ｇ２には１日目に通常の固体飼料を水とともに給餌した後、タールを体重１ｋｇ当たり１０ｍｇ腹腔投与し、以後７日間上記と同じ餌を給餌して、該期間中の動物の様子を観察した。表４に結果を示す。
5. Tar toxicity test (1)
Ten 6-week-old ICR mice (Semutako Co., Ulsan City, Gyeonggi-do, Korea) were divided into a herbal composition group (G1) and a control group (G2), and normal solid feed was fed with water for 2 weeks.
Among the ICR mice aged 8 weeks, G1 was fed with the herbal medicine-containing feed with water on the first day, and then 10 mg of tar was peritoneally administered per kg of body weight. Thereafter, the herbal medicine-containing feed was fed for 7 days, The state of the mouse during the period was observed.
On the other hand, after feeding a normal solid feed with water on G1 on the first day, G2 was given 10 mg of tar per kg body weight and then fed the same feed for 7 days. Observed. Table 4 shows the results.
Ｇ１（生薬組成物群）では、５匹中４匹がタールを投与して７日経過後に生存していたのに対し、Ｇ２（対照群）では、５匹中１匹がタールを投与して７日経過後に生存していた。このことから、生薬組成物（本発明品）の摂取がタールに対する解毒効果を高めることが分かった。 In G1 (herbal medicine composition group), 4 out of 5 animals received tar and survived after 7 days, whereas in G2 (control group) 1 out of 5 animals received tar. Survived after 7 days. From this, it was found that the intake of the herbal medicine composition (product of the present invention) enhances the detoxification effect on tar.
６．タール毒性試験（２）
４週齢のＩＣＲマウス（セムタコ社、韓国京畿道烏山市）２０匹を生薬組成物群と対照群に各１０匹ずつ分け、通常の固体飼料を水とともに１週間給餌した。
５週齢の生薬組成物群マウスには、１日目の１０時と１７時に前記生薬配合飼料を水とともに給餌するとともに、その日の１４時に、注射用滅菌蒸留水に１ｍｇ／ｍｌの濃度で溶解したニコチンを体重１ｋｇ当たり３０ｍｇ腹腔投与した。
以後、７日間上記と同じ餌を上記と同時刻に給餌して１週間後の生存率を調べた。
一方、５週齢の対照群マウスには、通常の固体飼料を水とともに給餌した以外は前記生薬組成物群と同様に行なった。表５に結果を示す。
6). Tar toxicity test (2)
Twenty 4-week-old ICR mice (Semutako Co., Ulsan, Gyeonggi-do, Korea) were divided into 10 each for a crude drug composition group and a control group, and a normal solid feed was fed with water for 1 week.
The herbal medicine composition group mice at 5 weeks of age were fed the herbal medicine-containing feed with water at 10:00 and 17:00 on the first day, and dissolved in sterile distilled water for injection at a concentration of 1 mg / ml at 14:00 on that day. The administered nicotine was administered 30 mg per kg body weight.
Thereafter, the same diet as above was fed at the same time as above for 7 days, and the survival rate after 1 week was examined.
On the other hand, control mice of 5 weeks of age were treated in the same manner as the herbal composition group except that a normal solid feed was fed with water. Table 5 shows the results.
生存率は、生薬組成物群が７０％、対照群が１０％となり、生薬組成物（本発明品）のタールに対する解毒効果が再確認された。 The survival rate was 70% for the herbal composition group and 10% for the control group, and the antidote effect of the herbal composition (product of the present invention) on tar was reconfirmed.
７．一酸化炭素毒性試験
９週齢までの給餌履歴は前記「２．ニコチン毒性試験（１）」と同様に行なった。
９週齢の各ＩＣＲマウスを露出用チャンバ（Sugiyamage社）内に収容して、Ｇ１とＧ３には０２２１％，ＣＯ５ｐｐｍの混合気体をポンプで取り入れて５分間吸入させた。露出終了後の各マウスを心臓採血し、血中ＣＯ-Ｈｂ濃度をガスクロマトグラフィーにより測定した。分析試料として、前記採血した血液０．５ｍｌを５ｍｌ容量の反応ガラス瓶に入れ、オクチルアルコールとポタシウムペリシアネイト飽和溶液０．２５ｍｌを加えて反応させたものを使用した。
一方、Ｇ２とＧ４には、０２２１％，ＣＯ５ｐｐｍの混合気体を５分間吸入させ、その後通常の固体飼料に生薬組成物を混ぜたものを給餌した後に心臓採血を行ない、前記と同様の方法により血中CO-Hb濃度を測定した。
分析試料はガスクロマトグラフィーにより定量した。分析条件は次のとおりである。
（ガスクロマトグラフィー装置）5890 SERIES，FID装着、ＨＰ社（U.S.））
（カラム）モレキュラーシーブ５Ａ（3/60 mesh）を充填した長さ２ｍ、直径３ｍｍのガラスカラム
（カラム温度）６０℃
（キャリア気体）Ｈ２
（流速）５０ｍｌ／ｍｉｎ
表６に結果を示す。
7). Carbon monoxide toxicity test The feeding history up to 9 weeks of age was the same as in “2. Nicotine toxicity test (1)”.
Each ICR mice 9 weeks of age and housed within the exposure chamber (Sugiyamage Co.), G1 and the G3 0 2 21%, was inhaled for 5 minutes to incorporate gas mixture CO5ppm pump. Each mouse after completion of exposure was subjected to heart blood sampling, and the blood CO-Hb concentration was measured by gas chromatography. As an analysis sample, 0.5 ml of the collected blood was placed in a 5 ml reaction glass bottle and reacted by adding 0.25 ml of octyl alcohol and saturated potassium periocyanate solution.
On the other hand, the G2 and G4 are 0 2 21%, a mixed gas of CO5ppm inhaled for 5 minutes, then subjected to cardiac bled conventional solid diet after feeding those mixed herbal composition, the same method as described Was used to measure the blood CO-Hb concentration.
The analytical sample was quantified by gas chromatography. The analysis conditions are as follows.
(Gas chromatography equipment) 5890 SERIES, FID installed, HP (US))
(Column) Glass column with 2m length and 3mm diameter packed with molecular sieve 5A (3/60 mesh) (column temperature) 60 ° C
(Carrier gas) H 2
(Flow rate) 50ml / min
Table 6 shows the results.
ＣＯ露出前に生薬組成物（本発明品）を給餌した生薬組成物群（Ｇ１，Ｇ２）と生薬組成物（本発明品）を給餌しなかった対照群（Ｇ３，Ｇ４）について血中ＣＯ−Ｈｂ濃度を比べると、前者の方が後者よりも有意に低い値を示した。このことから、生薬組成物（本発明品）は、ＣＯに対する解毒作用を有することが推測される。 Blood CO − for the crude drug composition group (G1, G2) fed with the crude drug composition (product of the present invention) before exposure to CO and the control group (G3, G4) not fed with the crude drug composition (product of the present invention) When the Hb concentration was compared, the former showed a significantly lower value than the latter. From this, it is presumed that the herbal medicine composition (product of the present invention) has a detoxifying action against CO.
８．ダイオキシン類に対する体外排泄作用
韓国の京畿道華城郡所在の焼却炉に１０年以上勤めている労働者のうち、志願者３名を被検者とした。該被検者には毎食後、生薬組成物１．２ｇを４週間摂取してもらった。そして、試験開始前と４週間経過後に、前記被検者の血中ダイオキシン類濃度をＧＣ−ＭＳにより測定した。分析は、US EPA methods ＆ Canada IOS methodsに準じて行なった。表７に結果を示す。
8). In vitro excretion of dioxins Among the workers who have worked in an incinerator in Hwaseong-gun, Gyeonggi-do, Korea, three volunteers were the subjects. The subject took 1.2 g of the herbal composition after each meal for 4 weeks. And the blood dioxin density | concentration of the said subject was measured by GC-MS before the test start and after four weeks progress. The analysis was performed according to US EPA methods & Canada IOS methods. Table 7 shows the results.
ＰＣＤＤ類（ＰＣＤＤＳ）とＰＣＤＥ類（ＰＣＤＦＳ）の合計濃度は、いずれの被検者についても３０％以上の減少率を示した。また、ＴＥＱ濃度は、いずれの被検者についても１０％以上の減少率を示した。これらの結果から、生薬組成物（本発明品）を摂取することにより、ダイオキシン類がヒト体内から体外へ排泄されることが分かった。 The total concentration of PCDDs (PCDD S ) and PCDEs (PCDF S ) showed a reduction rate of 30% or more for all subjects. Further, the TEQ concentration showed a decrease rate of 10% or more for any subject. From these results, it was found that dioxins are excreted from the human body to the outside by ingesting the herbal composition (the product of the present invention).
９．抗酸化力の測定
抗酸化力の測定はKiharuの方法（例えば、特開2002-38151号公報を参照）にしたがって行なった。すなわち、蒸留水１ｍｌにリノール酸２ｍｇを添加した溶液と、蒸留水１ｍｌにTween-20 １０ｍｇを添加した溶液と、１時間曝気させた０．２Ｍ リン酸カルシウム（ｐＨ７．４）１ｍｌと、生薬組成物（本発明品）０．５ｍｌからなる混合物を３７℃で２４時間反応させながら、３時間毎に反応液を０．１ｍｌ採取した。続いて、採取した反応液に７５％エタノールを９．７ｍｌ、３０％チオシアン酸アンモニウムを０．１ｍｌ、０．０２Ｍ硫酸アンモニウム鉄を３．５ｍｌ、塩酸を０．１ｍｌそれぞれ添加し、３分後に５００ｎｍにおける吸光度を測定した。また、比較例として合成抗酸化剤である２，６−ジ−ｔ−ブチル−４−メチルフェノール（ＢＨＴ）と天然抗酸化剤であるトコフェロールを用いて上記と同様に抗酸化力を測定した。表８に結果を示す。
9. Antioxidant power measurement Antioxidant power was measured according to the method of Kiharu (for example, see JP-A-2002-38151). That is, a solution obtained by adding 2 mg of linoleic acid to 1 ml of distilled water, a solution obtained by adding 10 mg of Tween-20 to 1 ml of distilled water, 1 ml of 0.2 M calcium phosphate (pH 7.4) aerated for 1 hour, and a herbal medicine composition ( (Invention product) While reacting a mixture of 0.5 ml at 37 ° C. for 24 hours, 0.1 ml of the reaction solution was sampled every 3 hours. Subsequently, 9.7 ml of 75% ethanol, 0.1 ml of 30% ammonium thiocyanate, 3.5 ml of 0.02M iron iron sulfate, and 0.1 ml of hydrochloric acid were added to the collected reaction solution, and after 3 minutes at 500 nm. Absorbance was measured. Further, as a comparative example, the antioxidant power was measured in the same manner as described above using 2,6-di-t-butyl-4-methylphenol (BHT) as a synthetic antioxidant and tocopherol as a natural antioxidant. Table 8 shows the results.
表８より、生薬組成物の抗酸化力は、トコフェロールより高く、ＢＨＴよりもやや低いことが分かった。 From Table 8, it was found that the antioxidant power of the herbal composition was higher than that of tocopherol and slightly lower than that of BHT.
１０．血漿総抗酸化力の測定
４週齢のＩＣＲマウス（セムタコ社、韓国京畿道烏山市）１６匹を生薬組成物群と対照群に各８匹ずつ分け、通常の固体飼料を水とともに１週間給餌した。
５週齢の各マウスのうち、生薬組成物群には前記生薬配合飼料を水とともに３週間給餌した後採血を行ない、血漿総酸化力を測定した。
一方、５週齢の対照群には、通常の固体飼料を水とともに３週間給餌したこと以外は上記と同様に行なった。
総抗酸化力は、総抗酸化力測定キット（Ｒａｎｄｏｘ社（U.K.））を用いて測定した。表９に結果を示す。
10. Measurement of total plasma antioxidant activity 16 ICR mice (Semutako, Ulsan-si, Gyeonggi-do, Korea), 16 weeks old, were divided into a crude drug composition group and a control group, each of which was fed with normal solid feed with water for 1 week. did.
Among the 5-week-old mice, the herbal medicine composition group was fed with the herbal medicine-containing feed together with water for 3 weeks, blood was collected, and the total plasma oxidative power was measured.
On the other hand, the control group of 5 weeks old was performed in the same manner as above except that a normal solid feed was fed with water for 3 weeks.
The total antioxidant power was measured using a total antioxidant power measuring kit (Randox (UK)). Table 9 shows the results.
表９に示したTrolox換算濃度は総抗酸化力の指標である。生薬組成物群の血漿総抗酸化力は対照群に比べて３８％増加した（ｐ＜０．０５）。血漿の抗酸化力は、体内の抗酸化力を代表すると一般的に考えられている。したがって、表９のデータから、生薬組成物（本発明品）の摂取により体内抗酸化力が増加したといえる。 The Trolox equivalent concentration shown in Table 9 is an index of total antioxidant power. The total plasma antioxidant power of the crude drug composition group increased by 38% compared to the control group (p <0.05). The antioxidant power of plasma is generally considered to represent the antioxidant power in the body. Therefore, from the data in Table 9, it can be said that the antioxidant power in the body increased due to the intake of the herbal medicine composition (the product of the present invention).
本発明は、例えば、食品、タバコ、医薬品、漢方薬などの配合原料として広く利用することができる。 The present invention can be widely used as a raw material for blending foods, tobacco, pharmaceuticals, traditional Chinese medicines, and the like.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006233544A JP4776474B2 (en) | 2006-08-30 | 2006-08-30 | Herbal medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006233544A JP4776474B2 (en) | 2006-08-30 | 2006-08-30 | Herbal medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008056589A JP2008056589A (en) | 2008-03-13 |
| JP4776474B2 true JP4776474B2 (en) | 2011-09-21 |
Family
ID=39239764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006233544A Expired - Fee Related JP4776474B2 (en) | 2006-08-30 | 2006-08-30 | Herbal medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4776474B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103487554A (en) * | 2013-09-24 | 2014-01-01 | 中国烟草总公司贵州省公司 | Detecting method for content of tar and carbonic oxide in cigarette mainstream smoke |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2601600C1 (en) * | 2015-05-21 | 2016-11-10 | федеральное государственное бюджетное образовательное учреждение высшего образования "Мичуринский государственный аграрный университет" | Method for production of jelly from garden nightshade sunberry for functional nutrition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002232115A1 (en) * | 2001-06-22 | 2003-01-08 | Council Of Scientific And Industrial Research | A process for the isolation of a major harmful oxidant from cigarette smoke |
| JP2003171310A (en) * | 2002-05-02 | 2003-06-20 | Noevir Co Ltd | Skin barrier function-reinforcing agent |
| KR100547495B1 (en) * | 2003-02-27 | 2006-01-31 | 주식회사 리젠 바이오텍 | Functional food composition with cotinine induction and antioxidant effect |
| KR100526760B1 (en) * | 2003-09-05 | 2005-11-08 | 김현석 | An oriental herb extracts composition having detoxification effect on the nicotine and dioxin |
-
2006
- 2006-08-30 JP JP2006233544A patent/JP4776474B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103487554A (en) * | 2013-09-24 | 2014-01-01 | 中国烟草总公司贵州省公司 | Detecting method for content of tar and carbonic oxide in cigarette mainstream smoke |
| CN103487554B (en) * | 2013-09-24 | 2015-03-04 | 中国烟草总公司贵州省公司 | Detecting method for content of tar and carbonic oxide in cigarette mainstream smoke |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008056589A (en) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta et al. | Nutritional and therapeutic values of Stevia rebaudiana: A review | |
| Milind et al. | Clove: a champion spice | |
| Bever | Oral hypoglycaemic plants in West Africa | |
| Bastos et al. | Yerba mate: pharmacological properties, research and biotechnology | |
| KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
| KR100913243B1 (en) | A drink composition for eliminating hangover | |
| KR100968109B1 (en) | Calcium?compound containing natural product composition for curing a hangover and preparation method thereof | |
| Asimi et al. | Herbs/spices as feed additive in aquaculture | |
| Chandra et al. | Therapeutic potential of Cichorium intybus in lifestyle disorders: a review | |
| WenYing et al. | Chicory seeds: a potential source of nutrition for food and feed | |
| Tagnaout et al. | Phytochemical study, antibacterial and antioxidant activities of extracts of Capparis spinosa L | |
| SHARANGİ et al. | Stevia: Medicinal Miracles and therapeutic magic | |
| CN109568538A (en) | Resolution composition of being still drank after a night comprising milk thistle, turmeric, Radix Glycyrrhizae and cassia seed | |
| KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
| US20060137702A1 (en) | Anti-cigarette herbal formulation as an antidote to tobacco | |
| JP4776474B2 (en) | Herbal medicine composition | |
| KR100823978B1 (en) | Herb extract for removing harmful elements accumulated in a human body and manufacturing method of the same | |
| WO2002066041A1 (en) | Natural composition | |
| KR950009178B1 (en) | A process of health food that prevents a bad effectof tabacco | |
| KR101046787B1 (en) | Hangover drink composition | |
| KR101470603B1 (en) | Manufacturing method of herbextract for removing harmful elements caused by smoking | |
| KR101987554B1 (en) | Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata | |
| KR100812968B1 (en) | A study of purifying hunman inner body with natural herbal plants | |
| Fatiqa Zafar et al. | Comparative evaluation of phytochemical, mineral and vitamin contents of gemmomodified extracts and leaves of two indigenous medicinal plants. | |
| CN115721685A (en) | Medicinal composition and application of pilea asteroides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100202 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110510 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110531 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110628 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140708 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |